IVAX Corporation has appointed Stephen Marcus, M.D. as senior vice president, proprietary pharmaceutical business development - IVAX Research, Inc. Dr. Marcus will report to Dr. Phillip Frost, chairman and CEO of IVAX.
Dr. Marcus has extensive drug development experience, including the development of new drugs to treat multiple sclerosis, various forms of cancer and other diseases. He has played a major role in IVAX' collaborations with the National Cancer Institute regarding a number of immunotoxins for cancer and HIV, as well as with IVAX' collaboration with Serono regarding cladribine for multiple sclerosis.
Dr. Marcus' entrepreneurial spirit and medical and scientific expertise will be invaluable as IVAX enters into further proprietary product collaborations around the world with other pharmaceutical companies.
Dr. Marcus joined IVAX Research as vice president, oncology and biotechnology in October 1999. Prior to joining IVAX Research, he held senior clinical research positions with Neurocrine Biosciences, Novartis Pharmaceuticals, Schering-Plough Corporation and Triton Biosciences, the biotechnology subsidiary of Shell Oil Company.